GSK 625019

Drug Profile

GSK 625019

Alternative Names: 625019; GSK625019; GW-625019

Latest Information Update: 26 Apr 2011

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antihyperglycaemics
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 26 Apr 2011 No development reported - Phase-I for Type-2 diabetes mellitus in USA (unspecified route)
  • 26 Apr 2011 No development reported - Phase-I for Metabolic syndrome in USA (unspecified route)
  • 28 Feb 2007 Phase-I clinical trials in Metabolic syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top